Mankind Pharma has announced its decision to form a committee aimed at evaluating various options for integrating Bharat Serums and Vaccines (BSV) into its operations. This move follows the successful completion of a Rs. 13,768 crore acquisition of BSV in October 2024. The company plans to explore different structural alternatives for the integration process, with a concrete plan expected to be presented to the board in the coming months. The proposal will undergo consultation with financial, legal, and tax advisors and will require approval from shareholders, creditors, and regulators.